Experimental virus therapy for colorectal cancer shows early promise but study halted

NCT ID NCT05733611

Terminated Disease control Sponsor: Replimune, Inc. Source: ClinicalTrials.gov ↗

First seen Feb 02, 2026 · Last updated Apr 26, 2026 · Updated 9 times

Summary

This study tested a new treatment for people with advanced colorectal cancer that did not respond to standard chemotherapy. The treatment combined a virus that attacks cancer cells (oncolytic immunotherapy) with two approved drugs (atezolizumab and bevacizumab). Only 5 people enrolled before the study was stopped early, so results are limited. The goal was to see if the combination could shrink tumors, but it is not a cure and ongoing management is still needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

USC Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
University of Washington Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States

Conditions

Explore the condition pages connected to this study.

MSS PMMR REFRACTORY METASTATIC COLORECTAL CANCER